Gastrointestinal stromal tumors, commonly abbreviated as GISTs, arise from the interstitial cells of Cajal or their precursors in the wall of the digestive tract. The majority of cases are driven by activating mutations in the KIT or PDGFRA receptor tyrosine kinase genes, and targeted drugs such as imatinib have transformed treatment for many patients. Yet resistance to tyrosine kinase inhibitors develops with sobering regularity, and secondary mutations in the kinase domain frequently blunt the effectiveness of later-line agents such as sunitinib and regorafenib. For patients whose tumors progress through all available targeted therapies, options remain severely limited. This therapeutic ceiling has pushed researchers to look beyond the kinase signaling axis itself and to ask what downstream and parallel programs allow GIST cells to survive, adapt, and spread. The new study addresses precisely that question by focusing on how the tumor’s metabolic and epigenetic machinery conspires to lock cells into a malignant state.

At the center of the investigation is lactylation, an epigenetic mark first described in 2019 that attaches lactate-derived lactyl groups to lysine residues on histone proteins, the spools around which DNA is wound. The discovery of histone lactylation resolved a long-standing puzzle: elevated lactate, long dismissed as a mere waste product of glycolysis, appeared to actively stimulate gene expression, but the mechanism was unknown. It is now understood that when cells engage in high rates of glycolysis, whether because of oxygen deprivation or because of the Warburg effect that characterizes many cancers, pyruvate is converted to lactate in large quantities, and a fraction of that lactate enters the nucleus. There, enzymes can transfer the lactyl group onto histone lysines, creating histone lactylation marks that physically loosen the interaction between histones and DNA and recruit reader proteins that activate transcription. In essence, a cell’s metabolic state can be written directly into its chromatin, turning genes on or off in response to how the cell feeds itself. In cancers, this creates a self-reinforcing loop in which the metabolic frenzy of the tumor rewrites its own gene expression program to become more aggressive.

The research team identified fibronectin 1, or FN1, as a critical node in this loop in GIST. Fibronectin 1 is a high-molecular-weight glycoprotein normally secreted into the extracellular matrix, where it mediates cell adhesion, migration, and wound healing. In many solid tumors, including several sarcoma subtypes, FN1 is overexpressed and is associated with invasion, metastasis, and poor clinical outcomes. The new work elevates FN1 from a passive correlate of aggressive disease to an active driver: the authors demonstrate that fibronectin 1 mediated histone lactylation promotes the malignant progression of GIST. In practical terms, the tumor’s own extracellular and metabolic environment, rich in lactate, appears to induce lactylation marks on histones that switch on a transcriptional program favoring proliferation, invasion, and survival, with fibronectin 1 both participating in and amplifying this program.

What makes the study particularly novel is the regulatory layer sitting above this process. The researchers show that the FN1-lactylation axis in GIST is regulated by m6A modification of RNA. N6-methyladenosine is a reversible chemical mark deposited on adenosine bases within messenger RNAs by writer enzymes of the METTL family, principally the METTL3–METTL14 complex, and removed by eraser enzymes such as FTO and ALKBH5. The consequences of m6A deposition depend on which reader proteins recognize the mark: YTHDF family proteins and YTHDC proteins can accelerate mRNA decay, enhance translation, or alter RNA processing and export. Over the past decade, m6A has emerged as a master regulator of cancer-relevant transcripts, and dysregulation of its writers, erasers, and readers has been documented across a wide range of malignancies. In this study, m6A modification acts as the conductor of the orchestra, determining the abundance and behavior of the FN1 message and thereby calibrating the intensity of the lactylation-driven malignant program.

The mechanistic chain the authors propose can be summarized as follows. Altered m6A dynamics in GIST cells, involving shifts in the activity of methyltransferases and demethylases, change how fibronectin 1 messenger RNA is processed, degraded, or translated, leading to elevated FN1 expression or enhanced FN1 function. Fibronectin 1, in turn, is tied to increased glycolytic flux and lactate accumulation, which fuel histone lactylation. The resulting lactylated histones activate promoters and enhancers of genes that promote malignancy, creating a feed-forward circuit in which epigenetic activation of metabolic and pro-invasive genes sustains the very metabolic conditions that generate the lactyl marks in the first place. Disrupting any point in this circuit, the study suggests, could weaken the loop and slow tumor progression. The authors’ experimental framework, combining molecular profiling of GIST specimens with mechanistic assays in cellular models, supports each link in this chain, although translating the full loop into clinical interventions will require further validation.

From a translational standpoint, the study offers several potential points of attack. Drugs that inhibit lactate production or export, such as inhibitors of lactate dehydrogenase A or monocarboxylate transporters, are already in preclinical and early clinical development for other cancers and could be repurposed for GIST. Similarly, small-molecule inhibitors of the m6A writer METTL3 have entered early-phase clinical trials, and compounds that modulate reader proteins are advancing rapidly. The lactylation machinery itself is also becoming druggable, as researchers have identified enzymes, including members of the p300 family of histone acetyltransferases and, more recently, deacylating enzymes capable of removing lactyl marks, that could be targeted to strip lactylation from histones. A combination strategy that simultaneously dampens lactate generation and blocks the m6A-dependent upregulation of FN1 could, in principle, collapse the entire feed-forward circuit that the study describes.

The work also carries important implications for biomarker development. Because fibronectin 1 is a secreted, matrix-associated protein and because m6A-related enzymes and histone lactylation marks can be measured by immunohistochemistry and sequencing-based assays, the molecular signature defined in this study could potentially be developed into a stratification tool. Patients whose tumors display high FN1 expression, strong lactylation marks, and dysregulated m6A machinery might be identified as having an elevated risk of progression or resistance to standard tyrosine kinase inhibitors, allowing clinicians to escalate therapy earlier or to enroll such patients in trials of metabolism- and epigenetics-targeted agents. Conversely, patients lacking this signature might be spared more aggressive interventions. Such stratification remains speculative until the findings are validated in larger, prospective cohorts, but the study provides the biological rationale needed to pursue it.

The broader scientific significance of the paper lies in its demonstration that three independently discovered layers of cellular regulation, RNA modification, protein lactylation, and chromatin state, do not operate in isolation but can be wired together into a coherent oncogenic circuit. Histone lactylation was originally characterized in macrophages responding to bacterial infection, where it linked inflammatory metabolism to gene activation, and it has since been implicated in tumors ranging from renal cell carcinoma to gastric and liver cancers. Studies linking m6A to lactate metabolism have begun to appear in other cancer types as well. By connecting these threads in GIST, a tumor type in which metabolic reprogramming had received comparatively little attention, the new research expands the conceptual map of how sarcomas progress and suggests that metabolism-epigenetics crosstalk may be a general feature of mesenchymal malignancies rather than a peculiarity of epithelial cancers.

Looking ahead, the authors and the field face clear next steps. The precise enzymes responsible for writing and erasing histone lactylation in GIST cells need to be definitively mapped, and the specific genomic loci whose activation depends on lactylated histones should be catalogued genome-wide to identify the full set of malignant effector genes downstream of FN1. Animal models of GIST, particularly patient-derived xenografts carrying KIT mutations, will be essential to test whether pharmacological disruption of the m6A–FN1–lactylation axis delays progression or sensitizes tumors to existing kinase inhibitors. Clinical validation in tissue banks from imatinib-treated patients could determine whether the signature predicts drug resistance. If those efforts succeed, a disease that has been treated almost exclusively through the lens of kinase signaling for the past two decades may gain an entirely new therapeutic dimension, one built on the chemistry of lactate, chromatin, and RNA.

Histone modifications, known to regulate gene expression profoundly by altering chromatin accessibility, have been intensively studied primarily through acetylation, methylation, and phosphorylation. However, histone lactylation, discovered only a few years ago, has emerged as a critical player linking cellular metabolism with epigenetic regulation. This study is among the first to connect histone lactylation mechanistically to tumor immunology, revealing how metabolic byproducts influence cancer progression.

Within the dense, fibrotic stroma of pancreatic ductal adenocarcinoma (PDAC), immune cells are often paradoxically abundant but dysfunctional, facilitating tumor growth rather than suppression. The authors report a direct epigenetic axis by which lactate—produced excessively through the cancer’s altered glycolytic metabolism—is utilized to catalyze histone lactylation, particularly on histone H3 lysine residues. This modification increases access to the CXCL1 gene locus, boosting its expression and reshaping the immune infiltration landscape.

CXCL1, a chemokine best known for its potent ability to recruit neutrophils, plays multifaceted roles in cancer biology. Zhang and colleagues demonstrate that increased CXCL1 expression creates a chemotactic gradient, drawing neutrophils into the tumor microenvironment. These tumor-associated neutrophils (TANs) are polarized towards an immunosuppressive phenotype, dampening anti-tumor T-cell responses and facilitating pancreatic cancer’s notorious immune evasion.

The researchers employed cutting-edge chromatin immunoprecipitation sequencing (ChIP-seq) to map histone lactylation marks across the pancreatic cancer genome. Their data revealed that CXCL1 is among the genes most significantly upregulated in response to histone lactylation, cementing the causal relationship between metabolic epigenetics and chemokine production. This specificity implies that targeting this pathway could selectively blunt pro-tumor inflammation without broadly disrupting immune function.

Further experimentation using murine models of PDAC confirmed that blocking histone lactylation via genetic or pharmacologic means drastically reduced CXCL1 levels and, consequently, neutrophil infiltration. These interventions corresponded with restored cytotoxic T-cell activity and slowed tumor progression, illustrating the pathway’s therapeutic potential. The team also explored the role of lactate transporters and enzymes involved in lactylation dynamics, identifying potential molecular targets for future drug development.

Intriguingly, the study links the metabolic remodeling characteristic of pancreatic tumors directly to the epigenetic landscape, demonstrating that tumor-induced alterations in glycolysis have a profound and precise consequence on immune regulation. This integrative view dissolves traditional barriers separating cancer metabolism and immunology, advocating for therapies that simultaneously modulate both domains.

The implications of this work extend beyond pancreatic cancer. Given that lactate accumulation and immune cell infiltration are common features in diverse solid tumors, histone lactylation may represent a universal mechanism tumors use to subvert immune surveillance. Consequently, modulators of histone lactylation enzymes could emerge as broad-spectrum agents, enhancing the efficacy of existing immunotherapies by reversing immune escape.

The study also underscores the complexity of neutrophil functions in cancer. Traditionally undervalued compared to lymphocytes, neutrophils are now recognized as pivotal regulators within the tumor microenvironment. By manipulating chemokine expression patterns, tumor cells can co-opt neutrophils to their advantage, highlighting the nuanced interplay between immune cell recruitment and functional polarization.

Beyond its immediate therapeutic prospects, this research opens new avenues for biomarker discovery. Elevated histone lactylation signatures or CXCL1 levels in tumor biopsies may serve as predictive markers for immune evasion intensity and responsiveness to combinatorial immunometabolic therapies. Such biomarkers could transform patient stratification and treatment personalization in pancreatic cancer, notoriously difficult to treat due to its heterogeneity.

From a technical perspective, the study leverages state-of-the-art epigenomic profiling and mouse models to provide causal and mechanistic insights rarely achieved at this resolution. The integration of metabolic flux analyses with epigenetic and immunological assays represents a methodological tour de force, exemplifying how multidisciplinary approaches can unveil novel cancer biology aspects.

Moreover, the findings have significant implications for the design of clinical trials. Immunotherapy, often hindered by the immunosuppressive tumor microenvironment in pancreatic cancer, may benefit from the adjunctive use of lactylation inhibitors or CXCL1 antagonists. Such combination therapies could rejuvenate anti-tumor immunity, potentially overcoming the resistance that currently limits checkpoint blockade success in this cancer type.

As scientists continue to unravel the complexities of tumor microenvironment interactions, this seminal work highlights the confluence of metabolism, epigenetics, and immunity as fertile ground for therapeutic innovation. Histone lactylation stands as a missing link elucidating how metabolic dysregulation in cancer cells translates into profound immunological consequences.

In conclusion, Zhang, Ma, Wan, and their team have illuminated a compelling mechanism by which pancreatic cancer exploits histone lactylation to elevate CXCL1 expression, orchestrating neutrophil-mediated immune suppression. This discovery not only enhances our understanding of tumor biology but also paves the way for novel intervention strategies that jointly target metabolic and immune escape pathways. As researchers and clinicians strive to tame pancreatic cancer’s lethality, targeting histone lactylation promises a beacon of hope in improving patient outcomes.

Subject of Research:
Epigenetic regulation via histone lactylation mediating immune escape and neutrophil infiltration in pancreatic cancer.

Article Title:
Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer.

Article References:

Zhang, P., Ma, J., Wan, Y. et al. Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer. Nat Commun (2026). https://doi.org/10.1038/s41467-026-69311-5

Image Credits: AI Generated

Histone lactylation is an emerging epigenetic modification that links metabolic changes, particularly in the tumor microenvironment, to gene expression alterations driving cancer development. This study leverages a multi-omics approach, integrating bulk RNA sequencing, single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics, to dissect the role of lactylation in GBM at unprecedented resolution. By probing datasets from GEO and TCGA, the team identified lactylation-related genes that are markedly upregulated in GBM tissues and are associated with immunosuppressive microenvironments and poor clinical outcomes.

A key finding centers around the discovery of distinct malignant tumor cell subpopulations exhibiting high levels of lactylation, which reside predominantly within hypoxic regions of the tumor core. These hypoxic niches are well-known for fostering aggressive tumor phenotypes that evade immune surveillance. Single-cell analyses revealed that these lactylated clusters undergo profound metabolic reprogramming, tailoring their gene expression to survive and thrive under oxygen-deprived conditions, while concurrently orchestrating mechanisms to suppress the surrounding immune response.

Spatial transcriptomics added another critical dimension to the findings by mapping the precise localization of these lactylated tumor cells within the heterogeneous tumor architecture. In particular, cells expressing high levels of S100A6, a gene intimately linked to lactylation, were found concentrated in aggressive tumor regions notorious for rapid proliferation and invasion. This spatial information underscores the functional heterogeneity within GBM and provides a tangible target for therapeutic interventions.

To translate these molecular insights into clinical practice, the researchers developed a prognostic risk model based on nine lactylation-associated genes. Using LASSO-Cox regression—a powerful statistical method for feature selection—they stratified GBM patients into distinct high- and low-risk groups. Strikingly, this model demonstrated impressive predictive accuracy with area under the curve (AUC) values ranging from 0.77 to 0.87, suggesting its potential utility as a robust biomarker panel for patient prognosis and treatment stratification.

The compelling prognostic value of the lactylation signature is further supported by experimental validation. In vitro functional assays targeting S100A6 demonstrated that silencing this gene significantly impaired GBM cell proliferation, migration, and invasion, highlighting its pivotal role in maintaining tumor aggressiveness. These findings position S100A6 not merely as a biomarker but as a potential therapeutic target for disrupting lactylation-driven malignant programs.

Underpinning these discoveries is the innovative application of SCENIC transcriptional network inference and CellChat intercellular communication modeling. These computational tools enabled the authors to uncover regulatory networks and cell-cell interactions modulated by lactylation, providing mechanistic insights into how tumor cells rewire signaling pathways to foster immune suppression and metabolic adaptation in GBM.

Pseudotime trajectory analyses further delineated the dynamic states of tumor cell populations, tracing the evolutionary paths from less aggressive to more malignant lactylated states. This temporal framework enriches our understanding of tumor progression and highlights critical junctures where therapeutic interventions might be most effective.

The study also sheds light on the tumor immune microenvironment, revealing that lactylation-associated clusters contribute to the establishment of immunosuppressive niches. This finding dovetails with accumulating evidence that metabolic reprogramming in tumors orchestrates immune evasion, a major challenge for immunotherapies in GBM.

Moreover, the emergence of lactylation as a key metabolic-epigenetic axis opens avenues for novel therapeutic strategies. Targeting enzymes responsible for lactylation or the downstream effectors, such as S100A6, could potentially disrupt malignant metabolic circuits, sensitize tumors to immune attack, or enhance the efficacy of existing treatments.

Beyond its immediate clinical relevance, this research marks a significant advance in cancer biology by employing integrated single-cell and spatial transcriptomics to parse tumor complexity. This multidimensional profiling affords a holistic view of cellular heterogeneity, spatial organization, and functional states within tumors—an approach likely to become foundational in precision oncology.

Despite these promising findings, challenges remain. Validation of the prognostic model and therapeutic targets in larger, independent patient cohorts and in vivo models will be essential to confirm their utility. Additionally, translating knowledge of lactylation into safe and effective clinical interventions will require comprehensive understanding of the broader systemic effects of modulating this epigenetic mark.

Nevertheless, this study underscores the transformative potential of marrying metabolic insights with high-resolution transcriptomic technologies to redefine our understanding of glioblastoma. By pinpointing lactylation as a central player in tumor cell clustering, metabolic adaptation, and immune modulation, it opens a new chapter in the fight against one of the deadliest brain cancers.

In summary, this pioneering work reveals that lactylation is more than a metabolic footnote in glioblastoma biology; it is a defining feature of tumor heterogeneity and aggressiveness. The identification of lactylation-enriched tumor cell clusters, spatially anchored in hypoxic niches and regulated by signatures including S100A6, provides a powerful prognostic tool and therapeutic target. This research paves the way for the development of lactylation-focused strategies that could revolutionize glioblastoma treatment and improve outcomes for patients facing this devastating disease.

Subject of Research: Metabolic reprogramming through histone lactylation in glioblastoma, its association with tumor heterogeneity, immune evasion, and prognosis.

Article Title: Single-cell and spatial transcriptomics reveal lactylation-associated tumor cell clusters and define a prognostic risk model in glioblastoma

Article References:
Han, R., Chi, G., Sun, D. et al. Single-cell and spatial transcriptomics reveal lactylation-associated tumor cell clusters and define a prognostic risk model in glioblastoma. BMC Cancer (2025). https://doi.org/10.1186/s12885-025-15291-6

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15291-6

Within the tumor microenvironment (TME), the metabolic reprogramming of cancer cells towards high glycolytic flux results in significant lactic acid and proton export, chiefly via monocarboxylate transporter 4 (MCT4). This export acidifies the extracellular space to a pH estimated at 6.5 to 6.8, profoundly impacting surrounding cells and molecular processes. Acidification not only degrades the extracellular matrix, facilitating invasion and metastasis, but also impairs the efficacy of chemotherapeutic drugs, particularly weak-base agents, by protonation-induced neutralization, which reduces their cellular uptake. This acidic milieu thus creates a physical and biochemical barrier against conventional therapies, presenting a formidable challenge for oncologists.

Paradoxically, cancer cells are adept at recycling the very lactic acid they expel. Through monocarboxylate transporter 1 (MCT1), tumor cells re-import lactate to fuel mitochondrial oxidative metabolism. This lactate utilization fosters oxidative phosphorylation within the tricarboxylic acid (TCA) cycle and promotes NADPH production via isocitrate dehydrogenase 1 (IDH1), contributing to redox balance and anabolic processes required for sustained proliferation. Notably, lactate also stimulates post-translational lactylation of DNA repair proteins such as NBS1 and MRE11. This lactylation enhances genomic stability and fortifies cancer cells against chemotherapeutic DNA damage, thereby contributing to the development of treatment resistance.

The immunosuppressive effects of lactate and its associated acidification in the TME manifest distinctly across immune cell populations. Tumor-associated macrophages (TAMs), through signaling via GPR81 and GPR132, are reprogrammed into an M2-like phenotype characterized by high IL-10 production and secretion of chemokines such as CCL17. This phenotype supports tumor metastasis and suppresses effective immune responses. Dendritic cells exposed to acidic stress experience disruption of TLR3 and STING pathways, resulting in impaired antigen presentation and accelerated antigen degradation. This functional impairment hampers the priming of adaptive immune responses vital for tumor surveillance.

Natural killer (NK) cells encounter profound functional suppression within the acidic TME. Intracellular acidification triggers apoptotic pathways leading to loss of cytotoxic granules and abrogation of interferon-gamma (IFN-γ) secretion, critical components of their tumoricidal repertoire. Intriguingly, tumor-intrinsic factors such as SIX1-mediated overexpression of lactate dehydrogenase A (LDHA) exacerbate this dysfunction, particularly in pancreatic cancer models. Regulatory T cells (Tregs) not only withstand but exploit elevated lactate. Lactate imported by Tregs fuels oxidative phosphorylation, sustaining their suppressive functions. Concurrently, lactate induces nuclear factor-kappa B (NF-κB)-dependent Foxp3 upregulation, MOESIN lactylation, and enhanced CTLA-4 mRNA splicing regulated by USP39, collectively reinforcing immunosuppressive circuits.

CD8⁺ cytotoxic T lymphocytes face a double metabolic jeopardy in the TME. Extracellular lactate hampers glycolysis by disrupting the NAD⁺/NADH ratio and impeding GLUT10 trafficking to the plasma membrane, thereby depriving these effector cells of necessary energy substrates. Moreover, acidification impairs cytoskeletal rearrangement essential for their infiltration and migration within tumor tissues. However, emerging evidence suggests a nuanced role for lactate: in carefully controlled concentrations, lactate can promote TCF1-dependent stemness programs in select CD8⁺ T-cell subsets, potentially enhancing their longevity and antitumor potential in specific contexts. This dichotomy underscores the complexity of lactate signaling in the immune microenvironment.

Beyond immune cells, stromal components such as cancer-associated fibroblasts (CAFs) significantly contribute to lactate-driven immunomodulation. CAFs respond to lactate exposure by secreting interleukin-8 (IL-8), a potent chemoattractant that promotes recruitment of TAMs and fosters an immunosuppressive niche by restraining CD8⁺ T-cell function and expanding Treg populations. Endothelial cells similarly adapt to the TME, importing lactate via MCT1 to maintain redox homeostasis and stabilize hypoxia-inducible factor 1-alpha (HIF-1α). This stabilization enhances vascular endothelial growth factor (VEGF) production, promoting angiogenesis that supports tumor growth and metastasis. Thus, lactate orchestrates a complex multicellular network that fortifies the immunosuppressive tumor niche.

In light of lactate’s centrality in tumor progression and immune evasion, therapeutic strategies targeting its metabolism are rapidly evolving. The first approach focuses on glycolytic inhibition using agents such as 2-deoxyglucose, oxamate, diclofenac, stiripentol, FX11, and gossypol to suppress LDHA activity and curtail lactate production. Concurrently, inhibitors like syrosingopine and AZD3965 target MCT1/4 to block lactate export, causing toxic intracellular accumulation of lactic acid and metabolic collapse. While promising, these approaches must balance efficacy with toxicity, as glycolysis is vital in many normal tissues.

The second therapeutic avenue leverages immune-potentiating combinations. Augmentation of tumor pH using oral bicarbonate or dichloroacetate-mediated LDHA inhibition alleviates lactate-induced immunosuppression. Further, depletion of ALKBH5, an RNA demethylase implicated in lactate metabolism, sensitizes tumors to immune checkpoint blockade such as anti-PD-1 therapy by reactivating CD8⁺ T and NK cells. These combinational strategies underscore the interplay between metabolic rewiring and immune modulation, paving the way for more effective immunotherapies.

Metabolic repurposing constitutes a third frontier in anti-lactate strategies. Lithium carbonate demonstrates promise by redirecting lactate into CD8⁺ T-cell mitochondria through MCT1 relocalization, rejuvenating oxidative metabolism and restoring cytotoxic function. Additionally, innovative gene-editing nanosystems combining lactate oxidase with signal regulatory protein alpha (SIRPα) fusion proteins have been engineered to simultaneously deplete lactate and reprogram TAMs toward a pro-inflammatory M1 phenotype. These advanced nanotechnologies achieve synergistic tumor phagocytosis and regression in preclinical models, representing a leap forward in metabolic-immunotherapy integration.

Despite these advances, significant challenges hinder translation into clinical success. On-target toxicities of LDHA and MCT inhibitors in glycolysis-dependent normal tissues demand precise therapeutic windows. Tumor metabolic heterogeneity, with some relying more heavily on oxidative phosphorylation than glycolysis, necessitates patient stratification for tailored treatments. Moreover, dosing strategies must avoid collateral damage to antitumor lymphocytes, highlighting the need for refined delivery systems and biomarker-guided therapy.

Looking forward, burgeoning research seeks to harness lactate-responsive drug delivery nanocarriers capable of selectively releasing therapeutics in acidic, lactate-rich TMEs, minimizing systemic exposure. Single-cell transcriptomic and metabolomic mapping of lactate-handling pathways will elucidate cell-type-specific vulnerabilities and intercellular metabolic crosstalk. Clinical validation of lithium-based metabolic adjuvants offers an achievable avenue for immediate impact. Collectively, reframing lactate from a mere metabolic exhaust to a druggable immune checkpoint heralds a paradigmatic shift with transformative potential for next-generation cancer immunotherapies.

This evolving paradigm underscores the profound duality of lactate in cancer biology—both as a metabolic substrate fueling tumor growth and as a cunning architect of immunosuppression. The intricate cellular choreography it orchestrates within the tumor microenvironment challenges conventional views and compels innovative therapeutic strategies. As research deepens, lactic acid stands poised to transition from an overlooked metabolite to a linchpin of metabolic-immunological interventions that promise to reinvigorate antitumor immunity and reshape oncologic treatment landscapes.

Subject of Research: Not applicable

Article Title: Burning lactic acid: a road to revitalizing antitumor immunity

News Publication Date: 9-Jun-2025

Web References: http://dx.doi.org/10.1007/s11684-025-1126-6

Image Credits: Jingwei Ma, Liang Tang, Jingxuan Xiao, Ke Tang, Huafeng Zhang, Bo Huang

Keywords: Health and medicine

Histone modifications have long captivated cancer researchers due to their profound influence on gene expression and cellular identity. Among these, acetylation and methylation have been extensively studied, laying the foundation for epigenetic therapies. However, histone lactylation, a relatively novel type of modification first described just a few years ago, introduces a metabolic dimension to epigenetic regulation by linking cellular metabolic states directly to gene expression outcomes. This revolutionary idea merges metabolic pathways with chromatin biology, offering fresh perspectives on how cancer cells adapt and thrive.

At its core, histone lactylation involves the addition of lactyl groups derived from lactate onto specific lysine residues of histone proteins. Lactate, a metabolic byproduct traditionally viewed as a waste molecule from anaerobic glycolysis, has gained recognition as an important signaling metabolite. In cancer cells, which frequently exhibit the Warburg effect—a preference for glycolysis even under oxygen-rich conditions—high levels of lactate accumulate within the tumor microenvironment. This surplus of lactate now emerges not just as a metabolic quirk but as a direct epigenetic modulator influencing gene expression via histone lactylation.

The implications of histone lactylation in immune evasion are particularly compelling. Tumor cells often create an immunosuppressive milieu that inhibits the activity of cytotoxic immune cells such as T lymphocytes and natural killer cells. Emerging evidence suggests that histone lactylation may facilitate this immune escape by modulating the transcription of key genes involved in immune checkpoints and cytokine production. This adaptive epigenetic mechanism thereby equips cancer cells with an enhanced ability to ‘hide’ from immune surveillance, posing a significant barrier to immune-based therapies.

Moreover, the role of histone lactylation in promoting therapy resistance is drawing intense attention. Resistance to chemotherapy and targeted therapies remains a leading cause of cancer treatment failure. Studies indicate that cancer cells with elevated histone lactylation levels exhibit a transcriptional profile skewed towards survival pathways and DNA repair mechanisms, making them resilient to traditional cytotoxic agents. This modification appears to act as a metabolic sensor that shifts gene expression to favor resistance phenotypes, underscoring the connection between metabolism, epigenetics, and therapeutic outcomes.

One particularly intriguing dimension of histone lactylation is its reversibility and dynamic regulation. Unlike irreversible genetic mutations, histone modifications are inherently plastic, enabling rapid adaptation of cancer cells to fluctuating environmental stresses. Understanding the enzymatic machinery responsible for writing, reading, and erasing the lactylation mark is an area of active research. Identifying specific lactyltransferases and delactylases could provide molecular targets for next-generation inhibitors designed to disrupt these adaptive epigenetic circuits.

The therapeutic potential of targeting histone lactylation extends beyond direct modulation of tumor cells. Since this modification regulates the expression of genes involved in immune evasion, it offers a promising strategy to enhance the efficacy of immunotherapies. Combining histone lactylation inhibitors with immune checkpoint blockade or adoptive cell therapies could synergistically restore immune competence against resistant tumors, raising hopes for more durable clinical responses.

Importantly, recent preclinical studies have begun to map the landscape of histone lactylation across different cancer types, revealing variable patterns that correlate with metabolic phenotypes and treatment responses. Tumors exhibiting high glycolytic flux and elevated lactate production tend to show robust lactylation signatures, highlighting histone lactylation as a metabolic-epigenetic biomarker. Such insights pave the way for personalized medicine approaches where patients’ tumors are profiled for lactylation status to tailor optimal therapeutic regimens.

Beyond oncology, histone lactylation is gaining recognition in various physiological and pathological contexts including inflammation, infection, and fibrosis. This modification’s involvement in immune cell differentiation and function points to a broader biological relevance. Thus, investigating the crosstalk between histone lactylation and other epigenetic marks continues to unravel complex regulatory networks that govern cell fate decisions in health and disease.

Technological advances such as high-resolution mass spectrometry, chromatin immunoprecipitation sequencing (ChIP-seq), and single-cell epigenomics have been instrumental in characterizing histone lactylation landscapes. These tools enable detailed mapping of lactylation sites and identification of gene targets affected by this modification, providing an essential framework for deciphering its functional consequences. Integration of metabolomics with epigenetic data further enriches understanding of how cellular metabolism and chromatin state co-evolve in cancer progression.

The intricate interplay between metabolism and epigenetics exemplified by histone lactylation underscores the need for interdisciplinary research bridging biochemistry, immunology, and clinical oncology. It challenges the traditional compartmentalization of scientific disciplines and calls for comprehensive approaches to tackle cancer’s adaptability. Future clinical trials evaluating agents that modulate histone lactylation pathways will be critical in translating this fundamental knowledge into tangible therapeutic benefits.

Despite the excitement, several critical questions remain unanswered. The full spectrum of enzymes regulating histone lactylation, the specificity of lactylation at different histone sites, and the downstream transcriptional networks modulated by these marks are subjects of ongoing investigation. Additionally, the potential off-target effects and safety profiles of lactylation-targeting drugs must be thoroughly evaluated before clinical application.

In conclusion, the discovery of histone lactylation as a nexus between cancer metabolism, epigenetic regulation, and immune evasion represents a paradigm shift in understanding tumor biology. By illuminating novel mechanisms driving therapy resistance, it heralds the emergence of innovative therapeutic strategies aiming to disrupt these adaptive processes. As research accelerates, targeting histone lactylation might soon become an integral component of precision oncology, offering renewed hope to patients facing refractory cancers.

Subject of Research: Histone lactylation as a novel epigenetic modification influencing cancer immune evasion and therapy resistance.

Article Title: Histone lactylation: a new target for overcoming immune evasion and therapy resistance.

Article References:
Ghadyani, F., Zandi, P. & Ghafouri-Fard, S. Histone lactylation: a new target for overcoming immune evasion and therapy resistance. Med Oncol 42, 399 (2025). https://doi.org/10.1007/s12032-025-02940-w

Image Credits: AI Generated